Skip to main content

Logos Global Management LP

13F filer · CIK 0001792126
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$2.32BU.S. long equity reported on 13F
Positions6825 new · 20 closed
Net flow last quarter-$24.7MBuys minus sells
Top 10 positions weight48.3%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202668 positions
ERASErasca, Inc.$223M9.58%3.89%+9.0%Q2 2024
ABVXAbivax S.A.$136M5.87%1.30%+51.7%Q3 2025
RVMDRevolution Medicines, Inc.$131M5.64%0.33%-65.0%Q1 2020
IDYAIDEAYA Biosciences, Inc.$112M4.81%3.11%-13.0%Q3 2021
BNTXBioNTech SE$94.4M4.07%0.40%Not reportedQ2 2020
VERAVera Therapeutics, Inc.$94.4M4.06%3.06%Not reportedQ4 2021
TNGXTango Therapeutics, Inc.$89.1M3.84%1.69%-5.0%Q3 2025
PRAXPraxis Precision Medicines, Inc.$87M3.75%0.93%-8.8%Q1 2024
CLDXCelldex Therapeutics, Inc.$78.1M3.36%2.68%+366.7%Q2 2020
DNTHDianthus Therapeutics, Inc.$78M3.36%1.46%+100.0%Q3 2025
CGONCG Oncology, Inc.$71.1M3.06%1.13%+73.9%Q1 2024
IRONDisc Medicine, Inc.$64M2.76%2.28%+56.3%Q1 2023
MAZEMaze Therapeutics, Inc.$57.7M2.49%3.49%+56.7%Q1 2025
DYNDyne Therapeutics, Inc.$56.6M2.44%1.54%+82.1%Q3 2020
MLTXMoonLake Immunotherapeutics$52.1M2.24%3.63%+78.3%Q4 2020
OCULOcular Therapeutix, Inc$52M2.24%2.41%+37.7%Q4 2023
DSGNDesign Therapeutics, Inc.$43.4M1.87%4.79%+53.9%Q1 2021
OLMAOlema Pharmaceuticals, Inc.$40.1M1.73%3.67%Not reportedQ4 2020
BLTEBelite Bio, Inc$38.5M1.66%0.64%NewQ2 2026
ACHVAchieve Life Sciences, Inc.$35.4M1.53%5.28%NewQ2 2026
TRVITrevi Therapeutics, Inc.$35.1M1.51%1.32%-21.7%Q1 2024
COGTCogent Biosciences, Inc.$34.8M1.50%0.52%Not reportedQ4 2020
AVBPArriVent BioPharma, Inc.$34.7M1.50%2.07%+185.7%Q1 2026
CBIOCrescent Biopharma, Inc.$34.2M1.47%6.85%+293.8%Q2 2025
CMPSCOMPASS Pathways plc$31.8M1.37%1.66%Not reportedQ3 2020
MLYSMineralys Therapeutics, Inc.$28.3M1.22%1.19%Not reportedQ1 2023
REPLReplimune Group, Inc.$27.7M1.19%2.98%NewQ2 2026
XENEXenon Pharmaceuticals Inc.$27.2M1.17%0.47%Not reportedQ3 2022
GPCRStructure Therapeutics Inc.$26.8M1.16%0.23%Not reportedQ1 2023
IMVTImmunovant, Inc.$25.6M1.10%0.32%-38.1%Q2 2020
JBIOJade Biosciences, Inc.$25M1.08%1.77%+181.3%Q2 2025
ELVNEnliven Therapeutics, Inc.$23.6M1.02%0.63%-13.9%Q1 2023
MANEVeradermics, Inc$22.1M0.95%0.43%+620.0%Q1 2026
AVTXAvalo Therapeutics, Inc.$21.3M0.91%2.17%+283.3%Q2 2024
RCUSArcus Biosciences, Inc.$20M0.86%0.51%-45.8%Q2 2023
SMMTSummit Therapeutics Inc.$19.7M0.85%0.17%NewQ2 2026
IMCRImmunocore Holdings plc$19.1M0.82%1.17%-60.0%Q3 2022
LBRXLB Pharmaceuticals Inc$19M0.82%2.04%-36.1%Q3 2025
NERVMinerva Neurosciences, Inc.$18.3M0.79%6.96%+2.3%Q4 2019
FTHFaeth Therapeutics, Inc.$18.1M0.78%2.80%+2306.7%Q1 2026
CRSPCRISPR Therapeutics AG$16.4M0.70%0.31%Not reportedQ1 2020
DBVTDBV Technologies S.A.$15M0.65%0.31%Not reportedQ2 2023
PBLSParabilis Medicines, Inc.$14.4M0.62%0.43%NewQ2 2026
RYTMRhythm Pharmaceuticals, Inc.$13.9M0.60%0.18%-72.2%Q3 2023
VORVor Biopharma Inc.$12M0.52%1.19%-13.3%Q4 2025
SRRKScholar Rock Holding Corp$11M0.47%0.16%Not reportedQ1 2022
IMMXImmix Biopharma, Inc.$10.3M0.44%1.40%-18.4%Q4 2025
QTTBQ32 Bio Inc.$10.2M0.44%3.37%NewQ2 2026
ODTXOdyssey Therapeutics, Inc.$9.76M0.42%1.09%NewQ2 2026
ANNXAnnexon, Inc.$8.57M0.37%1.00%Not reportedQ3 2020
Q1 2026Reported May 15, 202663 positions
RVMDRevolution Medicines, Inc.$195M9.71%1.00%Not reportedQ1 2020
ERASErasca, Inc.$180M9.01%3.59%-14.2%Q2 2024
IDYAIDEAYA Biosciences, Inc.$115M5.74%3.93%+10.4%Q3 2021
PRAXPraxis Precision Medicines, Inc.$91.8M4.58%1.02%-24.0%Q1 2024
CNTACentessa Pharmaceuticals PLC$84.4M4.21%1.37%+962.5%Q2 2021
TERNTerns Pharmaceuticals, Inc.$79.1M3.95%1.30%+100.0%Q4 2025
ABVXAbivax S.A.$75.2M3.75%0.86%+68.8%Q3 2025
TNGXTango Therapeutics, Inc.$62.8M3.13%2.08%-28.6%Q3 2025
CYTKCytokinetics Inc$57.7M2.88%0.71%+191.7%Q1 2020
OLMAOlema Pharmaceuticals, Inc.$47.8M2.39%3.67%Not reportedQ4 2020
UTHRUNITED THERAPEUTICS Corp$47.4M2.37%0.19%Not reportedQ2 2025
IMCRImmunocore Holdings plc$45.2M2.26%2.95%+76.5%Q3 2022
MDGLMadrigal Pharmaceuticals, Inc.$44.5M2.22%0.37%Not reportedQ4 2019
RYTMRhythm Pharmaceuticals, Inc.$39.1M1.95%0.66%+136.8%Q3 2023
CGONCG Oncology, Inc.$38.9M1.94%0.65%+187.5%Q1 2024
MAZEMaze Therapeutics, Inc.$36.9M1.84%2.48%+30.0%Q1 2025
BIIBBiogen Inc.$36.7M1.83%0.14%Not reportedQ1 2023
IRONDisc Medicine, Inc.$35.8M1.79%1.47%+9.8%Q1 2023
DNTHDianthus Therapeutics, Inc.$33.6M1.68%0.73%+27.0%Q3 2025
OCULOcular Therapeutix, Inc$32.6M1.63%1.76%+10.0%Q4 2023
TYRATyra Biosciences, Inc.$32.6M1.63%1.43%+304.8%Q3 2021
TRVITrevi Therapeutics, Inc.$28.6M1.43%1.87%+54.8%Q1 2024
MLTXMoonLake Immunotherapeutics$28M1.40%2.85%-14.3%Q4 2020
IMVTImmunovant, Inc.$26.7M1.33%0.53%-21.8%Q2 2020
XENEXenon Pharmaceuticals Inc.$26.2M1.31%0.47%Not reportedQ3 2022
RCUSArcus Biosciences, Inc.$25.9M1.29%0.96%Not reportedQ2 2023
DYNDyne Therapeutics, Inc.$25.4M1.27%0.85%+12.0%Q3 2020
GPCRStructure Therapeutics Inc.$24.1M1.20%0.23%-16.7%Q1 2023
LBRXLB Pharmaceuticals Inc$22.6M1.13%3.19%-23.8%Q3 2025
ELVNEnliven Therapeutics, Inc.$21.2M1.06%0.89%+58.8%Q1 2023
DSGNDesign Therapeutics, Inc.$20.7M1.04%3.12%-22.0%Q1 2021
NERVMinerva Neurosciences, Inc.$19.4M0.97%7.33%-2.9%Q4 2019
NAMSNewAmsterdam Pharma Co N.V.$19.2M0.96%0.51%+33.3%Q4 2025
MIRMMirum Pharmaceuticals, Inc.$18.5M0.92%0.33%-11.1%Q4 2025
PCVXVaxcyte, Inc.$17.4M0.87%0.21%-53.9%Q2 2020
ACADAcadia Pharmaceuticals Inc$16.7M0.83%0.44%-11.8%Q2 2022
CMPXCompass Therapeutics, Inc.$16.7M0.83%1.75%+173.9%Q3 2025
CLDXCelldex Therapeutics, Inc.$14.3M0.71%0.68%+28.6%Q2 2020
JANXJanux Therapeutics, Inc.$13.9M0.69%1.64%Not reportedQ2 2021
VORVor Biopharma Inc.$13.4M0.67%1.38%+650.0%Q4 2025
ALKSAlkermes plc.$12.4M0.62%0.21%Not reportedQ4 2024
ORICOric Pharmaceuticals, Inc.$12M0.60%0.92%+111.1%Q4 2025
IMMXImmix Biopharma, Inc.$11.2M0.56%2.31%+22.5%Q4 2025
TENXTenax Therapeutics, Inc.$9.99M0.50%2.57%NewQ1 2026
AMLXAmylyx Pharmaceuticals, Inc.$9.73M0.49%0.63%-26.3%Q3 2025
CBIOCrescent Biopharma, Inc.$8.86M0.44%1.75%-19.6%Q2 2025
SLNOSoleno Therapeutics Inc$8.37M0.42%0.48%-16.7%Q3 2023
AVBPArriVent BioPharma, Inc.$8.07M0.40%0.77%NewQ1 2026
RLAYRelay Therapeutics, Inc.$7.46M0.37%0.40%Not reportedQ3 2020
CRVSCorvus Pharmaceuticals, Inc.$6.58M0.33%0.54%-10.0%Q4 2025
Q4 2025Reported Feb 17, 202664 positions
RVMDRevolution Medicines, Inc.$159M9.63%1.02%+14.3%Q1 2020
PRAXPraxis Precision Medicines, Inc.$111M6.68%1.49%+200.0%Q1 2024
IDYAIDEAYA Biosciences, Inc.$108M6.53%3.56%+38.9%Q3 2021
OLMAOlema Pharmaceuticals, Inc.$80.2M4.85%3.94%Not reportedQ4 2020
CDTXCidara Therapeutics, Inc.$68.5M4.14%0.99%-17.3%Q2 2025
ABVXAbivax S.A.$53.9M3.26%0.51%-3.6%Q3 2025
ERASErasca, Inc.$48.4M2.92%4.57%-14.2%Q2 2024
OCULOcular Therapeutix, Inc$42.5M2.57%1.62%+7.7%Q4 2023
GPCRStructure Therapeutics Inc.$41.7M2.52%0.28%-29.4%Q1 2023
IRONDisc Medicine, Inc.$40.5M2.45%1.35%+13.3%Q1 2023
MAZEMaze Therapeutics, Inc.$39.4M2.38%1.93%-22.6%Q1 2025
TNGXTango Therapeutics, Inc.$37.2M2.25%3.09%+342.1%Q3 2025
RNAMAvidity Biosciences, Inc.$36.1M2.18%0.33%-16.7%Q2 2020
BIIBBiogen Inc.$35.2M2.13%0.14%+100.0%Q1 2023
IMVTImmunovant, Inc.$35M2.11%0.68%+400.0%Q2 2020
JAZZJazz Pharmaceuticals plc$34M2.05%0.33%Not reportedQ4 2024
TERNTerns Pharmaceuticals, Inc.$30.3M1.83%0.67%NewQ4 2025
PCVXVaxcyte, Inc.$30M1.81%0.50%+4.0%Q2 2020
IMCRImmunocore Holdings plc$29.5M1.78%1.68%Not reportedQ3 2022
LBRXLB Pharmaceuticals Inc$26.7M1.61%4.74%+6.2%Q3 2025
DYNDyne Therapeutics, Inc.$24.5M1.48%0.76%-47.9%Q3 2020
DSGNDesign Therapeutics, Inc.$23.5M1.42%4.14%-31.6%Q1 2021
MLTXMoonLake Immunotherapeutics$23.1M1.39%3.32%Not reportedQ4 2020
ACADAcadia Pharmaceuticals Inc$22.7M1.37%0.50%Not reportedQ2 2022
RYTMRhythm Pharmaceuticals, Inc.$20.3M1.23%0.28%-5.0%Q3 2023
TRVITrevi Therapeutics, Inc.$19.4M1.17%1.21%-29.6%Q1 2024
CYTKCytokinetics Inc$19.1M1.15%0.24%Not reportedQ1 2020
MIRMMirum Pharmaceuticals, Inc.$17.8M1.07%0.43%NewQ4 2025
QUREuniQure N.V.$16.2M0.98%1.08%+125.0%Q4 2019
NAMSNewAmsterdam Pharma Co N.V.$15.8M0.95%0.39%NewQ4 2025
KNSAKiniksa Pharmaceuticals International, plc$14.4M0.87%Not reportedNot reportedQ1 2021
SLNOSoleno Therapeutics Inc$13.9M0.84%0.57%Not reportedQ3 2023
JANXJanux Therapeutics, Inc.$13.8M0.83%1.66%+7.0%Q2 2021
NERVMinerva Neurosciences, Inc.$13.3M0.80%7.65%Not reportedQ4 2019
VSTMVerastem, Inc.$13.1M0.79%2.19%-58.0%Q1 2020
DNTHDianthus Therapeutics, Inc.$13M0.78%0.73%+57.5%Q3 2025
AMLXAmylyx Pharmaceuticals, Inc.$11.5M0.69%0.86%-34.5%Q3 2025
KYMRKymera Therapeutics, Inc.$10.1M0.61%0.16%-48.0%Q3 2020
CLDXCelldex Therapeutics, Inc.$9.51M0.57%0.53%Not reportedQ2 2020
NRIXNurix Therapeutics, Inc.$9.49M0.57%0.49%Not reportedQ3 2020
CGONCG Oncology, Inc.$8.3M0.50%0.25%Not reportedQ1 2024
ACLXArcellx, Inc.$7.5M0.45%0.20%-30.3%Q2 2023
CBIOCrescent Biopharma, Inc.$7.12M0.43%2.18%Not reportedQ2 2025
CMPXCompass Therapeutics, Inc.$6.18M0.37%0.64%-43.9%Q3 2025
JBIOJade Biosciences, Inc.$6.09M0.37%0.80%-36.8%Q2 2025
TYRATyra Biosciences, Inc.$5.52M0.33%0.39%Not reportedQ3 2021
ELVNEnliven Therapeutics, Inc.$5.24M0.32%0.57%Not reportedQ1 2023
IMMXImmix Biopharma, Inc.$5.23M0.32%1.89%NewQ4 2025
CNTACentessa Pharmaceuticals PLC$5M0.30%0.13%-61.9%Q2 2021
NGNENeurogene Inc.$4.02M0.24%1.26%NewQ4 2025
Q3 2025Reported Nov 14, 202553 positions
RVMDRevolution Medicines, Inc.$81.7M7.33%0.92%+2.9%Q1 2020
IDYAIDEAYA Biosciences, Inc.$61.2M5.49%2.57%-32.7%Q3 2021
AKROAkero Therapeutics, Inc.$57M5.11%1.50%Not reportedQ3 2022
ARVNArvinas, Inc.$47.5M4.26%7.87%+68.9%Q3 2024
OCULOcular Therapeutix, Inc$38M3.41%1.86%+47.7%Q4 2023
CDTXCidara Therapeutics, Inc.$35.9M3.22%1.28%+97.4%Q2 2025
VSTMVerastem, Inc.$35.8M3.21%6.07%+305.0%Q1 2020
ABVXAbivax S.A.$35.2M3.16%0.66%NewQ3 2025
ERASErasca, Inc.$33M2.96%5.34%+1.0%Q2 2024
MAZEMaze Therapeutics, Inc.$31.8M2.85%2.55%+100.6%Q1 2025
OLMAOlema Pharmaceuticals, Inc.$31.4M2.82%4.67%Not reportedQ4 2020
IMCRImmunocore Holdings plc$30.9M2.77%1.68%+47.8%Q3 2022
DYNDyne Therapeutics, Inc.$30.4M2.72%1.68%+26.3%Q3 2020
IRONDisc Medicine, Inc.$29.7M2.67%1.29%-35.7%Q1 2023
DSGNDesign Therapeutics, Inc.$27.5M2.47%6.42%-13.3%Q1 2021
JAZZJazz Pharmaceuticals plc$26.4M2.36%0.33%-55.6%Q4 2024
RNAMAvidity Biosciences, Inc.$26.1M2.34%0.41%-36.8%Q2 2020
GPCRStructure Therapeutics Inc.$23.8M2.13%0.47%Not reportedQ1 2023
JANXJanux Therapeutics, Inc.$22.9M2.05%1.56%-6.5%Q2 2021
PCVXVaxcyte, Inc.$22.5M2.02%0.48%Not reportedQ2 2020
RYTMRhythm Pharmaceuticals, Inc.$20.2M1.81%0.30%+53.9%Q3 2023
TRVITrevi Therapeutics, Inc.$20.1M1.80%1.72%+158.8%Q1 2024
PTGXProtagonist Therapeutics, Inc$19.9M1.79%0.48%Not reportedQ4 2021
AMLXAmylyx Pharmaceuticals, Inc.$19.7M1.77%1.32%NewQ3 2025
LBRXLB Pharmaceuticals Inc$17.8M1.60%4.47%NewQ3 2025
QUREuniQure N.V.$17.5M1.57%0.48%Not reportedQ4 2019
KYMRKymera Therapeutics, Inc.$14.2M1.27%0.35%Not reportedQ3 2020
BIIBBiogen Inc.$14M1.26%0.07%-50.0%Q1 2023
ACLXArcellx, Inc.$13.5M1.21%0.29%Not reportedQ2 2023
KROSKeros Therapeutics, Inc.$13.4M1.21%2.09%-57.5%Q2 2020
CNTACentessa Pharmaceuticals PLC$12.7M1.14%0.39%Not reportedQ2 2021
TNGXTango Therapeutics, Inc.$7.98M0.72%0.85%NewQ3 2025
DNTHDianthus Therapeutics, Inc.$7.87M0.71%0.47%NewQ3 2025
COGTCogent Biosciences, Inc.$7.18M0.64%0.36%Not reportedQ4 2020
CMPXCompass Therapeutics, Inc.$7.18M0.64%1.15%NewQ3 2025
CBIOCrescent Biopharma, Inc.$7.13M0.64%4.32%+8.4%Q2 2025
ELVNEnliven Therapeutics, Inc.$6.96M0.62%0.57%-2.9%Q1 2023
IMRXImmuneering Corp$6.65M0.60%3.66%NewQ3 2025
PRAXPraxis Precision Medicines, Inc.$6.63M0.59%0.59%-44.4%Q1 2024
SRRKScholar Rock Holding Corp$6.52M0.58%0.18%Not reportedQ1 2022
JBIOJade Biosciences, Inc.$5.39M0.48%1.92%Not reportedQ2 2025
EPRXEupraxia Pharmaceuticals Inc.$5.31M0.48%2.53%NewQ3 2025
IMVTImmunovant, Inc.$4.43M0.40%0.16%Not reportedQ2 2020
PHVSPharvaris N.V.$3.74M0.34%0.28%NewQ3 2025
ATXSAstria Therapeutics, Inc.$3.64M0.33%0.89%-28.6%Q4 2022
PEPGPepGen Inc.$3.47M0.31%2.29%NewQ3 2025
ACRSAclaris Therapeutics, Inc.$2.85M0.26%1.38%-18.9%Q2 2021
UNCYUnicycive Therapeutics, Inc.$2.06M0.19%2.27%0.0%Q1 2024
ESPREsperion Therapeutics, Inc.$1.99M0.18%0.37%NewQ3 2025
SEPNSepterna, Inc.$1.57M0.14%0.19%-23.5%Q4 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.